Payment overview · 2025
General Payments
$2,512.06
87 reported records · 23 companies
Healthcare provider profile · identity verified
David Selzer, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WEST PALM BEACH, FL · NPI 1194069377
Verified facts
What the public records show
CMS Open Payments records show David Selzer, M.D. received $2,512.06 in general payments during 2025 across 87 reported records.
Novo Nordisk Inc accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Prolia, Rybelsus, Veltassa, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 570 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Gemtesa by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $812.04 | 32.3% | 24 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $441.81 | 17.6% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $283.17 | 11.3% | 15 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $138.95 | 5.5% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $88.57 | 3.5% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $88.44 | 3.5% | 4 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $73.77 | 2.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.37 | 2.9% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.65 | 2.7% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $68.17 | 2.7% | 2 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $43.78 | 1.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.51 | 1.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $41.78 | 1.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $41.15 | 1.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.92 | 1.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.80 | 1.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.59 | 1.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.07 | 1.0% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $22.87 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $20.21 | 0.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.80 | 0.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.86 | 0.7% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $14.78 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,512.06 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $569.03 | 16 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $283.17 | 15 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $200.72 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $197.23 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $155.06 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $138.95 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $88.44 | 4 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $73.77 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $68.65 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $68.17 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.99 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.65 | 2 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $43.78 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.51 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.51 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $41.15 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.09 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.80 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 102 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 49 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 347 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 160 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 177 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 570 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 77 | exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 58 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
101 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
77 | 25 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
70 | 23 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
160 | 39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
347 | 106 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
347 | 106 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
177 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
89 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
570 | 103 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
77 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
102 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
49 | 21 |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 676 | 234 |
| Atorvastatin Calcium | Atorvastatin Calcium | 582 | 197 |
| Ozempic | Semaglutide | 570 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 441 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 375 | 145 |
| Jardiance | Empagliflozin | 347 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 346 | 123 |
| Metformin Hcl | Metformin Hcl | 341 | 114 |
| Hydrochlorothiazide | Hydrochlorothiazide | 319 | 103 |
| Ezetimibe | Ezetimibe | 296 | 101 |
| Losartan Potassium | Losartan Potassium | 269 | 96 |
| Metformin Hcl Er | Metformin Hcl | 249 | 87 |
| Alprazolam | Alprazolam | 248 | 106 |
| Zolpidem Tartrate | Zolpidem Tartrate | 216 | 97 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 209 | 72 |
| Gabapentin | Gabapentin | 208 | 84 |
| Mounjaro | Tirzepatide | 177 | 36 |
| Sertraline Hcl | Sertraline Hcl | 175 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 59 |
| Kerendia | Finerenone | 160 | 39 |
| Omeprazole | Omeprazole | 158 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 60 |
| Famotidine | Famotidine | 156 | 61 |
| Furosemide | Furosemide | 148 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 142 | 46 |
| Lisinopril | Lisinopril | 141 | 56 |
| Montelukast Sodium | Montelukast Sodium | 138 | 52 |
| Memantine Hcl Er | Memantine Hcl | 136 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 122 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 42 |
| Allopurinol | Allopurinol | 116 | 42 |
| Simvastatin | Simvastatin | 104 | 37 |
| Eliquis | Apixaban | 102 | 36 |
| Linzess | Linaclotide | 101 | 33 |
| Valsartan | Valsartan | 91 | 23 |
| Trulicity | Dulaglutide | 89 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 78 |
| Clonazepam | Clonazepam | 86 | 34 |
| Trazodone Hcl | Trazodone Hcl | 83 | 41 |
| Baclofen | Baclofen | 81 | 36 |
| Potassium Chloride | Potassium Chloride | 79 | 29 |
| Rybelsus | Semaglutide | 77 | 20 |
| Synthroid | Levothyroxine Sodium | 77 | 25 |
| Finasteride | Finasteride | 73 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 72 | 57 |
| Lokelma | Sodium Zirconium Cyclosilicate | 70 | 23 |
| Lorazepam | Lorazepam | 67 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 67 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 25 |
| Carvedilol | Carvedilol | 62 | 20 |
| Bupropion Xl | Bupropion Hcl | 61 | 22 |
| Donepezil Hcl | Donepezil Hcl | 61 | 26 |
| Atenolol | Atenolol | 59 | 17 |
| Methylprednisolone | Methylprednisolone | 59 | 53 |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 28 |
| Veltassa | Patiromer Calcium Sorbitex | 58 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 40 |
| Myrbetriq | Mirabegron | 55 | 12 |
| Ramipril | Ramipril | 55 | 19 |
| Diazepam | Diazepam | 53 | 21 |
| Aripiprazole | Aripiprazole | 52 | 17 |
| Tramadol Hcl | Tramadol Hcl | 52 | 24 |
| Chlorthalidone | Chlorthalidone | 51 | 16 |
| Propranolol Hcl | Propranolol Hcl | 51 | 14 |
| Azithromycin | Azithromycin | 50 | 45 |
| Gemtesa | Vibegron | 49 | 21 |
| Valacyclovir | Valacyclovir Hcl | 48 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 23 |
| Ipratropium Bromide | Ipratropium Bromide | 45 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 13 |
| Repatha Sureclick | Evolocumab | 41 | suppressed |
| Mirtazapine | Mirtazapine | 40 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 30 |
| Spironolactone | Spironolactone | 40 | 11 |
| Meloxicam | Meloxicam | 39 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 11 |
| Farxiga | Dapagliflozin Propanediol | 38 | 13 |
| Irbesartan | Irbesartan | 36 | 16 |
| Januvia | Sitagliptin Phosphate | 36 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Colchicine | Colchicine | 34 | 17 |
| Primidone | Primidone | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Repaglinide | Repaglinide | 30 | 16 |
| Telmisartan | Telmisartan | 30 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 20 |
| Wegovy | Semaglutide | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | 14 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 28 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Prednisone | Prednisone | 25 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Ssd | Silver Sulfadiazine | 23 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 17 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | 11 |
| Scopolamine | Scopolamine | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,512.06 · 87 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Assure WCD, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, Flector, GARDASIL 9, GEMTESA, Hillrom - Carnation Ambulatory Monitor, JARDIANCE, Kerendia, Korlym, LEQVIO, Licart, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, TZIELD, Tirosint, UBRELVY, VERQUVO, VYNDAQEL, Veltassa, Veozah, Wegovy, ZEPBOUND, ZORYVE | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error